论文部分内容阅读
目的:研究CYP3A和GSTM1基因多态性与非霍奇金淋巴瘤(NHL)化疗疗效、毒副作用之间的相关性。方法:收集初治90例头颈部NHL患者和60名正常人及60例非肿瘤住院患者的外周静脉血,提取DNA,以PCR技术检测CYP3A和GSTM1等位基因型,采用CHOP方案治疗患者,比较不同的基因型患者化疗疗效和毒副作用的差别。结果:NHL患者CYP3A突变基因(A-44)频率为66.7%,GSTM1缺失基因频率为58.9%,与正常人两种基因型的分布频率(62.5%和53.3%)差异无统计学意义,χ2值为1.114和0.643,P值均>0.05。W和WM基因型的有效率分别为100.0%(4/4)和92.3%(48/52),均明显高于M基因型患者的29.4%(10/34),χ2值分别为4.930和37.037,P值均<0.05;含GSTM1非缺失基因型(+)的患者(0+Ⅰ期+Ⅱ期)白细胞下降89.2%,缺失基因型(-)患者(0+Ⅰ+Ⅱ期)白细胞下降67.9%,差异有统计学意义,P<0.05。结论:CYP3A和GSTM1基因多态性不增加NHL的患病风险,但能影响NHL患者化疗疗效及毒副作用。
Objective: To investigate the relationship between the CYP3A and GSTM1 gene polymorphisms and non-Hodgkin’s lymphoma (NHL) chemotherapy efficacy and side effects. Methods: Peripheral venous blood was collected from 90 newly diagnosed head and neck NHL patients, 60 normal subjects and 60 non-tumor inpatients. DNA was extracted and CYP3A and GSTM1 alleles were detected by PCR. CHOP regimen was used to treat patients. Comparison of different genotypes in patients with chemotherapy efficacy and toxicity differences. Results: The frequency of CYP3A mutation (A-44) was 66.7% and the frequency of GSTM1 deletion was 58.9% in NHL patients. There was no significant difference between the two genotype distribution frequencies (62.5% and 53.3%) in NHL patients, 1.114 and 0.643, P values were> 0.05. The genotype rates of W and WM were 100.0% (4/4) and 92.3% (48/52), respectively, which were significantly higher than those in M genotype (29.4%, 10/34), respectively, and the χ2 values were 4.930 and 37.037 (P <0.05). The number of leukocytes decreased 89.2% in patients with GSTM1 non-deletion genotype (+0) and in leukemia patients (0 + Ⅰ + Ⅱ) %, The difference was statistically significant, P <0.05. Conclusion: CYP3A and GSTM1 gene polymorphisms do not increase the risk of NHL, but can affect the chemotherapy efficacy and side effects of NHL patients.